SCHEMBL1116630

SCHEMBL1116630

O=C(NC1CC1)c1cccnc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.78
L3MBTL1 Q9Y468 2/20 0.78
HTT P42858 1/20 0.75
MAPT P10636 2/20 0.69
SMN1; SMN2 Q16637 1/20 0.65
GRM5 P41594 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
RAB9A P51151 1/20 0.60
TSHR P16473 1/20 0.57
CYP46A1 Q9Y6A2 1/20 0.56
THRB P10828 1/20 0.56
LMNA P02545 1/20 0.56
HIF1A Q16665 1/20 0.56
MMP2 P08253 2/20 0.54
ANPEP P15144 2/20 0.54
ROCK2 O75116 1/20 0.54
ROCK1 Q13464 1/20 0.54
GAA P10253 1/20 0.54
GFER P55789 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5783791 0.94 ALDH1A1 (0.71) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL3427705 0.93 ALDH1A1 (0.74) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL3427969 0.93 ALDH1A1 (0.70) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL19691213 0.92 ALDH1A1 (0.69) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL19691212 0.92 ALDH1A1 (0.69) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL12424958 0.92 ALDH1A1 (0.69) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL10143960 0.92 ALDH1A1 (0.77) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
SCHEMBL4414127 0.92 ALDH1A1 (0.77) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL3194885 0.91 ALDH1A1 (0.67) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL3194878 0.91 ALDH1A1 (0.67) ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897866-B1 AN ANTIMICROBIAL COMPOSITION UNILEVER IP HOLDINGS B V (NL) 2025-11-05 EP claimed
US-12311044-B2 Antimicrobial composition CONOPCO, INC. (US) 2025-05-27 US claimed
CN-119654130-A Use of a composition for enhancing night repair related functions of skin 联合利华知识产权控股有限公司 2025-03-18 CN claimed
CN-117915890-A Deodorant composition 联合利华知识产权控股有限公司 2024-04-19 CN claimed
CN-113242751-B Antimicrobial compositions 联合利华知识产权控股有限公司 2023-09-19 CN claimed
CN-111787903-B Disinfectant composition 联合利华知识产权控股有限公司 2023-08-15 CN claimed
US-20220087914-A1 AN ANTIMICROBIAL COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2022-03-24 US claimed
EP-3897866-A1 AN ANTIMICROBIAL COMPOSITION Unilever IP Holdings B.V. (NL) 2021-10-27 EP claimed
CN-113242751-A Antimicrobial compositions 联合利华知识产权控股有限公司 2021-08-10 CN claimed
WO-2020126347-A1 AN ANTIMICROBIAL COMPOSITION UNILEVER N.V. (NL) 2020-06-25 WO claimed
US-8163771-B2 11 β-HSD1 modulators EXELIXIS, INC. (US) 2012-04-24 US claimed
EP-2308874-A1 Useful beta-lactamase inhibitors Basilea Pharmaceutica AG (CH) 2011-04-13 EP claimed
EP-2280966-A1 AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS Exelixis, Inc. (US) 2011-02-09 EP claimed
US-20100105675-A2 11 BETA-HSD1 MODULATORS EXELIXIS, INC. (US) 2010-04-29 US claimed
US-20090247515-A1 11 Beta-HSD1 Modulators EXELIXIS, INC. (US) 2009-10-01 US claimed
WO-2009114173-A1 AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS EXELIXIS, INC. (US) 2009-09-17 WO claimed
WO-2006068410-A1 NOVEL 3-(2-AMINO-6-PYRIDINYL)-4-HYDROXYPHENYL AMINE DERIVATIVES LG LIFE SCIENCES, LTD. (KR) 2006-06-29 WO claimed
EP-4702006-A1 USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XVI BASF SE (DE) 2026-03-04 EP disclosed
US-4436912-A 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor ELI LILLY AND COMPANY (US) 1984-03-13 US disclosed
US-4430499-A 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1984-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105675-A2 11 BETA-HSD1 MODULATORS HSD11B1, HSD11B2, HSD3B1 ALDH1A1 53/4885L3MBTL1 2364/4885HTT 2641/4885
US-12311044-B2 Antimicrobial composition DPM1, THPO, FPR1 ALDH1A1 2349/4885L3MBTL1 2696/4885HTT 3103/4885
US-20090247515-A1 11 Beta-HSD1 Modulators HSD11B1, HSD11B2, HSD3B1 ALDH1A1 68/4885L3MBTL1 2934/4885HTT 2632/4885
US-20220087914-A1 AN ANTIMICROBIAL COMPOSITION THPO, BROX, FPR1 ALDH1A1 2160/4885L3MBTL1 2800/4885HTT 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.